BTIG analyst Sung Ji Nam reiterated a Buy rating on BioNano Genomics (NASDAQ:BNGO) Inc on Monday, setting a price target of $10, which is approximately 84.16% above the present...
BTIG analyst Sung Ji Nam maintained a Buy rating on BioNano Genomics (NASDAQ:BNGO) Inc on Friday, setting a price target of $10, which is approximately 64.47% above the present...
Oppenheimer analyst Kevin DeGeeter reiterated a Buy rating on BioNano Genomics (NASDAQ:BNGO) Inc on Tuesday, setting a price target of $14, which is approximately 162.17% above the...
After soaring in the pre-market upon the release of its earnings report, shares of BioNano Genomics (NASDAQ:BNGO)are down 3% in mid-day trading. Although there was a lot to like in...
Bionano Genomics, Inc. provides genome analysis software solutions. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight. The company also provides Saphyr and Bionano compute servers; and NxClinical which offers one system for analysis and interpretation of genomic variants from microarray and next-generation sequencing data for cytogenetics and molecular genetics. In addition, it offers testing and laboratory services comprising FirstStepDx PLUS, a chromosomal microarray for identifying an underlying genetic cause in individuals with autism spectrum disorder, developmental delay, and intellectual disability; Fragile X syndrome (FXS) testing services; NextStepDx PLUS, a exome sequencing test to identify genetic variants that are associated with disorders of childhood development; EpiPanelDx PLUS, a genetic testing panel for patients who have experienced seizures, infantile spasms, encephalopathy, or febrile seizures; PGx test, which identifies over 60 alleles in 11 genes. The company was founded in 2003 and is headquartered in San Diego, California.
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Sell | Buy | Strong Buy | Strong Buy | Buy |
| Technical Indicators | Neutral | Strong Buy | Strong Buy | Strong Buy | Sell |
| Summary | Neutral | Strong Buy | Strong Buy | Strong Buy | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 40.76 | 41.53 | 39.61 | +0.34 | +0.84% | 29.89M | NYSE | |||
| 32.75 | 32.75 | 31.68 | +0.90 | +2.83% | 5.21M | NYSE | |||
| 49.65 | 49.86 | 47.53 | +1.63 | +3.39% | 42.60K | NYSE | |||
| 18.87 | 19.09 | 18.12 | +0.17 | +0.91% | 11.35M | NYSE | |||
| 6.96 | 7.23 | 6.855 | -0.140 | -1.97% | 416.73K | NASDAQ | |||
| 2.58 | 2.60 | 2.489 | +0.080 | +3.20% | 44.25K | NASDAQ | |||
| 7.65 | 7.67 | 7.60 | -0.07 | -0.91% | 3.04M | NASDAQ | |||
| 13.95 | 13.98 | 13.19 | +0.7300 | +5.52% | 129.87K | NASDAQ | |||
| 6.07 | 6.47 | 6.00 | -0.410 | -6.33% | 617.25K | NASDAQ | |||
| 4.40 | 4.40 | 4.40 | 0.00 | 0.00% | 5.39K | OTC Markets | |||
| 0.67 | 0.73 | 0.60 | -0.19 | -22.32% | 15.11M | NASDAQ | |||
| 19.35 | 19.60 | 19.21 | +0.25 | +1.31% | 23.55K | NASDAQ | |||
| 478.12 | 479.10 | 469.03 | +11.93 | +2.56% | 772.23K | NASDAQ | |||
| 3.00 | 3.15 | 2.72 | +0.2300 | +8.30% | 16.16M | NASDAQ | |||
| 8.37 | 9.05 | 8.11 | -0.58 | -6.48% | 164.84K | NASDAQ |